Plasbumin-20

Phase 3Small molecule

HHealthgen Biotechnology Corp.

Plasbumin-20 is one of 6 small molecule programs targeting Hypoalbuminemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoalbuminemiaActive, not recruiting

HypoalbuminemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Hypoalbuminemia

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Approved

—2

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

1 3

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Phase 3

2 4

Plasbumin-20

HHealthgen Biotechnology Corp.

Phase 3

1 5

Osrhsa

HHealthgen Biotechnology Corp.

Phase 3

1 6

Recombinant Human Chymotrypsin(osrhct)

HHealthgen Biotechnology Corp.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoalbuminemia1 trial

A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia

Completed·HHealthgen Biotechnology Corp.·Phase 3·NCT06355479·328 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Plasbumin-20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plasbumin-20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plasbumin-20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Healthgen Biotechnology Corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHealthgen Biotechnology Corp.

Plasbumin-20

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoalbuminemia1 trial

References

Drug Info

Quick Facts

Related News